Hemoglobin A1c (HbA1c) testing is the most effective method to diagnose pre-diabetes and diabetes, and point-of-care testing devices enhance screening ability in a number of settings. According to a Technavio report, the global POC HbA1C testing market is expected to grow at a CAGR of 8.60% during the forecast period 2017-2021. There are a wide variety of POC HbA1c testing devices available on the market, which promotes quick detection of diabetes and pre-diabetes. For instance, the DCA Vantage analyzer from Siemens Healthineers is a reliable option for the diagnosis of diabetes and identification of patients at risk of developing diabetes.
According to the market report, the key factor boosting the growth of the POC HbA1C testing market is the increase in equipment rental agreements. The high adoption of molecular POC testing is also identified as a primary growth driver for the global POC HbA1C testing market through 2021. Geographically, the POC HbA1c market is segmented as the Americas, APAC and EMEA. End users include hospitals, clinical diagnostic laboratories, and home care settings. However, the report notes that lack of skilled professionals to conduct POC diagnosis is a challenge that may restrain the market's growth.
Market trends reported during the forecast period include: increasing online marketing services for POC diagnosis, multi-analyte menus for combined POC HbA1C tests, and data management and connectivity to EHRs through interoperability.
Key players in the market include Abbott Laboratories, Alere, Bio-Rad Laboratories, Diazyme Laboratories, ARKRAY, EKF Diagnostics, OSANG Healthcare, Menarini Diagnostics, PTS Diagnostics, F. Hoffmann-La Roche, Siemens, Tosoh Bioscience and Trinity Biotech.